Recipharm, the contract development and manufacturing organisation (CDMO), has appointed a new director of business management for the USA and Canada to accelerate growth in the region.
With over 8 years of experience working in the North American CDMO industry, Kieran Chouhan joins the business management team at Recipharm to lead sales activity in North America.
In his new role, Kieran will be responsible for sales and business development for the CDMO's commercial manufacturing services.
Kenth Berg, Vice President Business Management said: "We are thrilled to welcome Kieran to the Recipharm team to help drive sales and business development activity in North America. We are fully committed to achieving our goals there by offering first class development and manufacturing services. I am certain Kieran's experience will be an asset to the team throughout that journey."
Having established an extensive network of customers and secured substantial projects in North America, Kieran's wealth of experience and market knowledge will support Recipharm's growth ambitions in the US market.
Kieran said: "Recipharm's knowledge and end-to-end offering means it can cater for customised and challenging projects, which will be a great asset in the North American market in the coming years. I'm delighted to be joining the team in its quest for growth and global expansion."
Kenth Berg, Vice President Business Management, email@example.com, +46 8 6025 216
For media enquiries, please contact Kate Hindhaugh at ramarketing: firstname.lastname@example.org, + 44 (0)191 222 1242, www.ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, LinkedIn: /ramarketing
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm's turnover is approximately SEK 6.0 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
(c) 2019 Cision. All rights reserved., source Press Releases - English